In prostate cancer that recurs after prostatectomy, adding an antiandrogen to salvage radiotherapy improves survival and other outcomes.

The addition of 24 months of antiandrogen therapy with bicalutamide to radiation therapy improved OS among patients with prostate cancer who have evidence of disease recurrence following radical ...

Cite this: Management Options for Gynaecomastia and Breast Pain Associated With Nonsteroidal Antiandrogen Therapy - Medscape - Mar 01, 2003.

Antiandrogen withdrawal (AAWD) results in a prostate-specific antigen (PSA) response (decline in PSA level of ≥ 50%) in 15% to 30% of androgen-independent prostate cancer (AiPCa) patients. Thereafter, ...

A protein that confers a worse prognosis in bladder cancer when present in high levels may be regulated by androgens, suggesting a role for antiandrogen agents in the treatment of this disease ...

A nearly two-decades-long clinical trial has demonstrated that adding antiandrogen therapy to radiation therapy can improve the survival of prostate cancer patients who have evidence of disease ...

In a secondary analysis of NRG Oncology/RTOG 9601, some patients had no survival benefit from long-term antiandrogen treatment. Adding 2 years of antiandrogen therapy to salvage radiation may harm ...

Antiandrogen therapy with daily bicalutamide to salvage radiation therapy resulted in significantly higher rates of long-term overall survival.

Cyproterone acetate, a synthetic progestogen with antiandrogen effects, is currently approved in most European countries but not in the U.S. Across Europe, the drug has varying indications ...

Castration resistance occurs in most patients with metastatic hormone-sensitive prostate cancer who are receiving androgen-deprivation therapy. Replacing androgens before progression of the disease ...

The antiandrogen withdrawal syndrome (AAWS) is characterized by tumour regression and declines in serum PSA levels on discontinuation of antiandrogens or other hormonal agents Initially reported ...